What's new — Hepatocellular carcinoma¶
Generated 2026-11-01 from the publication dates of every paper cited in this condition's pages.
This page answers a different question from the curation log. The log says when we last edited a page; this says how recent the evidence on those pages is — so you can tell settled ground from a field that is actively moving, and jump straight to what has emerged lately.
How much of this condition's evidence is recent¶
| Published within | Cited papers |
|---|---|
| last week | 1 |
| last month | 3 |
| last 2 months | 15 |
| last 3 months | 17 |
| last 6 months | 19 |
| last year | 24 |
| older than a year | 323 |
Counts are cumulative: a paper from last week also counts inside "last month". Dates are PubMed publication or e-publication dates, so a paper may have appeared online before its journal issue.
Newest evidence first¶
The most recent cited papers, with the pages that use them.
| Published | Paper | Cited on |
|---|---|---|
| 2026-11-01 | The aMAP Score Effectively Stratifies Hepatocellular Carcinoma Risk in the Steatotic Liver Disease Population — Liver Int ([PMID 42904608](https://pubmed.ncbi.nlm.nih.gov/42904608/){target="_blank" rel="noopener"}) | mash-masld-hcc |
| 2026-10-09 | Inequalities in hepatocellular carcinoma (HCC) surveillance uptake in London: a UK multicentre cohort study — BMJ Public Health ([PMID 42866364](https://pubmed.ncbi.nlm.nih.gov/42866364/){target="_blank" rel="noopener"}) | surveillance-and-early-detection |
| 2026-10-06 | First-line durvalumab and tremelimumab in poor-prognosis unresectable hepatocellular carcinoma: Phase IIIb single-arm SIERRA study — J Hepatol ([PMID 42838226](https://pubmed.ncbi.nlm.nih.gov/42838226/){target="_blank" rel="noopener"}) | systemic-therapy |
| 2026-10-01 | NCCN Guidelines® Insights: Hepatocellular Carcinoma, Version 2.2026 — J Natl Compr Canc Netw ([PMID 42874666](https://pubmed.ncbi.nlm.nih.gov/42874666/){target="_blank" rel="noopener"}) | guidelines |
| 2026-10-01 | Immune Checkpoint Inhibitor-Based Downstaging Therapy for Hepatocellular Carcinoma — JAMA Oncol ([PMID 42821267](https://pubmed.ncbi.nlm.nih.gov/42821267/){target="_blank" rel="noopener"}) | liver-transplantation |
| 2026-10-01 | Correction to Lancet Oncol 2026; 27: 1077-93 — Lancet Oncol ([PMID 42805209](https://pubmed.ncbi.nlm.nih.gov/42805209/){target="_blank" rel="noopener"}) | clinical-trials-landscape, guidelines, locoregional-therapy |
| 2026-10-01 | Global burden of cancer attributable to infections in 2024: a worldwide incidence analysis — Lancet Oncol ([PMID 42805198](https://pubmed.ncbi.nlm.nih.gov/42805198/){target="_blank" rel="noopener"}) | epidemiology-and-etiology |
| 2026-09-06 | Circulating tumor DNA and recurrence after curative-intent treatment of hepatocellular carcinoma: A systematic review and meta-analysis — Surg Oncol ([PMID 42715861](https://pubmed.ncbi.nlm.nih.gov/42715861/){target="_blank" rel="noopener"}) | biomarkers |
| 2026-09-03 | IHPBA 2026 global guideline for the management of hepatocellular carcinoma in resource-constrained healthcare settings — HPB (Oxford) ([PMID 42869716](https://pubmed.ncbi.nlm.nih.gov/42869716/){target="_blank" rel="noopener"}) | guidelines |
| 2026-09-02 | Multi-target blood test for hepatocellular carcinoma early detection: A cross-sectional analysis of the prospective ALTUS study — J Hepatol ([PMID 42800682](https://pubmed.ncbi.nlm.nih.gov/42800682/){target="_blank" rel="noopener"}) | biomarkers, surveillance-and-early-detection |
| 2026-09-02 | Pooled Individual Patient-Data Analysis of Clinical Trials on Second-line Multikinase Inhibitors Following Immunotherapy in Hepatocellular Carcinoma — JHEP Rep ([PMID 42800536](https://pubmed.ncbi.nlm.nih.gov/42800536/){target="_blank" rel="noopener"}) | systemic-therapy |
| 2026-09-02 | Steatotic Liver Disease Risk Scores to Predict Cirrhosis and Hepatocellular Carcinoma — JAMA Intern Med ([PMID 42766290](https://pubmed.ncbi.nlm.nih.gov/42766290/){target="_blank" rel="noopener"}) | mash-masld-hcc |
| 2026-09-01 | Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: results from the CheckMate 459 phase III trial — JHEP Rep ([PMID 42762856](https://pubmed.ncbi.nlm.nih.gov/42762856/){target="_blank" rel="noopener"}) | biomarkers, molecular-landscape |
| 2026-09-01 | Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study — Lancet Oncol ([PMID 42636832](https://pubmed.ncbi.nlm.nih.gov/42636832/){target="_blank" rel="noopener"}) | clinical-trials-landscape, guidelines, locoregional-therapy |
| 2026-09-01 | Transarterial Chemoembolization Plus Thermal Ablation in Unresectable Hepatocellular Carcinoma: The Phase 3 TORCH Randomized Clinical Trial — JAMA Oncol ([PMID 42530948](https://pubmed.ncbi.nlm.nih.gov/42530948/){target="_blank" rel="noopener"}) | clinical-trials-landscape, locoregional-therapy |
| 2026-08-07 | BEACON-HCC: Best evidence and North American consensus on treatment allocation for hepatocellular carcinoma — Hepatology ([PMID 42565685](https://pubmed.ncbi.nlm.nih.gov/42565685/){target="_blank" rel="noopener"}) | guidelines |
| 2026-08-03 | Liver transplant allocation by milan criteria may exclude eligible HCC patients without survival benefit - a post-hoc analysis of the SiLVER study — Dig Liver Dis ([PMID 42669573](https://pubmed.ncbi.nlm.nih.gov/42669573/){target="_blank" rel="noopener"}) | liver-transplantation |
| 2026-07-01 | Transarterial chemoembolization (TACE) with or without immune checkpoint inhibitors in unresectable hepatocellular carcinoma: a meta-analysis of randomized clinical trials — ESMO Gastrointest Oncol ([PMID 42582959](https://pubmed.ncbi.nlm.nih.gov/42582959/){target="_blank" rel="noopener"}) | locoregional-therapy |
| 2026-06-09 | Transarterial Embolization Alone Versus Drug-Eluting Microspheres Chemoembolization for Hepatocellular Carcinoma (RAD-18-TAcE): A Multicenter Randomized Clinical Trial — Cardiovasc Intervent Radiol ([PMID 42265476](https://pubmed.ncbi.nlm.nih.gov/42265476/){target="_blank" rel="noopener"}) | clinical-trials-landscape, locoregional-therapy |
| 2026-05-01 | Hepatocellular carcinoma attributable to hepatitis B, hepatitis C and other risk factors at global, regional and national levels: an updated systematic review and meta-analysis — Gut ([PMID 42135055](https://pubmed.ncbi.nlm.nih.gov/42135055/){target="_blank" rel="noopener"}) | cirrhosis-and-risk-stratification, epidemiology-and-etiology, overview |
| 2026-05-01 | Second-line TKI after first-line immunotherapy-based treatment in advanced HCC: Reconstructed IPD meta-analysis — JHEP Rep ([PMID 42128139](https://pubmed.ncbi.nlm.nih.gov/42128139/){target="_blank" rel="noopener"}) | systemic-therapy |
| 2026-01-02 | Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma — J Hepatol ([PMID 41580093](https://pubmed.ncbi.nlm.nih.gov/41580093/){target="_blank" rel="noopener"}) | clinical-trials-landscape, surgical-resection-and-ablation |
| 2025-11-06 | Practice changing RCT design and rationale: Abbreviated MRI plus AFP vs. ultrasound plus AFP for HCC surveillance in cirrhosis (PREMIUM study) — JHEP Rep ([PMID 41624484](https://pubmed.ncbi.nlm.nih.gov/41624484/){target="_blank" rel="noopener"}) | surveillance-and-early-detection |
| 2025-11-01 | Transarterial chemoembolization combined with immunotherapy and targeted therapy as first-line treatment for unresectable and non-metastatic hepatocellular carcinoma: a meta-analysis of phase III trials — Ther Adv Gastroenterol ([PMID 41268044](https://pubmed.ncbi.nlm.nih.gov/41268044/){target="_blank" rel="noopener"}) | locoregional-therapy |
Trials — what has moved¶
46 registered trials are cited by this condition's pages. Registry records were re-checked live when this page was generated, so status, enrolment and results-posting below reflect ClinicalTrials.gov as of that date.
| Registry activity | Trials |
|---|---|
| trial records updated in the last week | 2 |
| trial records updated in the last month | 4 |
| trial records updated in the last 2 months | 8 |
| trial records updated in the last 3 months | 11 |
| trial records updated in the last 6 months | 17 |
| trial records updated in the last year | 28 |
Recently updated registrations¶
Posted efficacy and safety results¶
Trials whose sponsors have posted results to the registry. Adverse-event figures are participant counts summed across all arms as reported — read them against enrolment, and follow the registry link for the arm-by-arm breakdown that determines whether a signal is real.
| Results posted | Trial | Phase | N | Primary outcome | Serious AE | Other AE | Deaths |
|---|---|---|---|---|---|---|---|
| 2026-10-28 | Nivolumab With or Without Relatlimab for Patients With Potentially Res | PHASE1 | 31 | Number of Patients Precluded From Surgery | 5 | 29 | 8 |
| 2026-09-03 | Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab ( | PHASE3 | 480 | Progression Free Survival (PFS) Per Response Evaluation Criteria in So | 184 | 463 | 253 |
| 2026-04-24 | Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuv | PHASE3 | 959 | Recurrence-Free Survival (RFS) | 162 | 628 | 218 |
| 2023-11-18 | A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as | PHASE3 | 668 | Recurrence-Free Survival (RFS), as Determined by IRF | 124 | 470 | 58 |
| 2023-06-18 | Study of Durvalumab and Tremelimumab as First-line Treatment in Patien | PHASE3 | 1324 | Overall Survival (OS) - Treme 300 mg x1 Dose + Durva 1500 mg vs Sora 4 | 435 | 1099 | 958 |
| 2021-11-05 | A Study of Atezolizumab in Combination With Bevacizumab Compared With | PHASE3 | 558 | Overall Survival (OS) in the Global Population | 288 | 642 | 477 |
| 2018-09-25 | A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and S | PHASE3 | 954 | Overall Survival (OS) | 358 | 938 | 817 |
| 2017-06-05 | Study of Regorafenib After Sorafenib in Patients With Hepatocellular C | PHASE3 | 573 | Overall Survival (OS) | 286 | 528 | 500 |
| 2010-09-27 | A Phase III Study of Sorafenib in Patients With Advanced Hepatocellula | PHASE3 | 602 | Overall Survival (OS) | 719 | 1129 | 0 |
36 of these trials are still recruiting or active — see the condition's clinical trials page for the full landscape.
Which pages rest on the newest evidence¶
🔥 marks a page citing three or more papers from the last year — the pages worth re-reading if you have been away.
| Page | Newest citation | In last year | Total citations |
|---|---|---|---|
| mash-masld-hcc | 2026-11-01 | 2 | 27 |
| surveillance-and-early-detection | 2026-10-09 | 3 | 29 |
| systemic-therapy | 2026-10-06 | 3 | 29 |
| clinical-trials-landscape | 2026-10-01 | 5 | 25 |
| epidemiology-and-etiology | 2026-10-01 | 2 | 26 |
| guidelines | 2026-10-01 | 5 | 34 |
| liver-transplantation | 2026-10-01 | 2 | 28 |
| locoregional-therapy | 2026-10-01 | 6 | 30 |
| biomarkers | 2026-09-06 | 3 | 29 |
| molecular-landscape | 2026-09-01 | 1 | 28 |
| cirrhosis-and-risk-stratification | 2026-05-01 | 1 | 25 |
| overview | 2026-05-01 | 1 | 36 |
| surgical-resection-and-ablation | 2026-01-02 | 1 | 26 |
| patient-experience-and-advocacy | 2025-10-01 | 0 | 25 |
| staging-and-treatment-allocation | 2025-09-02 | 0 | 25 |
| red-flags-and-safety-concerns | 2025-06-06 | 0 | 25 |
| diagnosis-and-imaging | 2025-06-02 | 0 | 25 |
Recency is not quality: an old paper may be the definitive one, and a new paper may not replicate. Use this to find movement, not to rank evidence. See open questions for what remains unresolved, and the curation log for when these pages were last revised.